Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.20%
#2 aelf aelf +23.74%
#3 Bitway Bitway +16.31%
#4 Decred Decred +11.24%
#5 TRIA TRIA +8.49%
#6 Wibx Wibx +8.11%
#7 Pons Pons +7.97%
#8 DexNet DexNet +7.55%
#9 Status Status +7.12%
#10 AtomOne AtomOne +7.07%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Settings
Language
ENGLISH
Currency
USD
Theme
Argenica Therapeutics Ltd Argenica Therapeutics Ltd

Argenica Therapeutics Ltd

AGN
Rank in Stocks #30343
Argenica Therapeutics Limited, a biotechnology company, engages in the research... Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Australia.
Share Price
$0.13400411
Market Cap
$17.21M
Change (1 day)
-7.32%
Change (1 year)
-70.34%
Country
AU
Trade Argenica Therapeutics Ltd (AGN)

Category

Healthcare
Earnings for Argenica Therapeutics Ltd (AGN)
Earnings in 2026 TTM: 0
According to Argenica Therapeutics Ltd latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Argenica Therapeutics Ltd from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE